Cargando…

Therapeutic Approach of Very Early-Onset Inflammatory Bowel Disease in a Loeys–Dietz Syndrome Child

Heterozygous TGFBR2 loss-of-function mutation is an extremely rare cause of very-early onset inflammatory bowel disease (VEOIBD) as, so far, only three cases have been reported in the literature. VEOIBD therapeutic management remains a real challenge for clinicians. Here, we described an interesting...

Descripción completa

Detalles Bibliográficos
Autores principales: Opréa, Alina, Collardeau-Frachon, Sophie, Heissat, Sophie, Peretti, Noel, Lachaux, Alain, Duclaux-Loras, Rémi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158452/
https://www.ncbi.nlm.nih.gov/pubmed/37168749
http://dx.doi.org/10.1097/PG9.0000000000000139
Descripción
Sumario:Heterozygous TGFBR2 loss-of-function mutation is an extremely rare cause of very-early onset inflammatory bowel disease (VEOIBD) as, so far, only three cases have been reported in the literature. VEOIBD therapeutic management remains a real challenge for clinicians. Here, we described an interesting new case of Loeys–Dietz syndrome presenting severe, very early intestinal inflammation associated with dysmorphic features, aortic arch tortuosity joint hyper laxity and severe scoliosis. TGFBR2 Sanger sequencing revealed a missense mutation c.1583G>A (p.Arg528His). As endoscopy confirmed a severe colitis, we chose a classical IBD therapeutic approach. We finally obtained remission under Ustekinumab (90 mg/6 weeks).